摘要
肠促胰素类药物利拉鲁肽(1iraglutide,商品名Victoza)具有显著降糖、改善β细胞功能、降低低血糖风险、减少体质量、降低收缩压等作用,在改善血糖控制的同时,为糖尿病患者带来多种降糖外益处,解决了现有降糖治疗存在的一些问题,在糖尿病治疗领域将拥有广泛的应用空间。
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2012年第24期2001-2003,共3页
Chinese Journal of Hospital Pharmacy
参考文献19
-
1Russell-Jones D. Molecular, pharmacological and clinical as pects of liraglutide, a once-daily human GLP / analogue [J]. Mol Cell Endocrinol, 2(/09, 297(1- 2):137- 140.
-
2Knudsen LB, Knudsen SM, Wilken M, et al. Plasma protein binding of NN221l, a long-acting derivative of GLP-1, is im portant for its efficacy [J]. Diabetes, 2003, 52:A321- A322.
-
3Elbr nd B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmaeodynamies, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide I derivative, in healthy male subjects [J]. Diabetes Care, 2002, 25:1398 - 1404.
-
4Marre M, Shaw J, Brandle M, et al. I.iraglutide, a once daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in sub jects with Type 2 diabetes (LEAI>1 SU) [J]. Diabetic Medi cine, 2009, 26:268-278.
-
5Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAI) (liraglutide effect and action in diabetes) 2 study [J]. Diabe tes (;are, 2(}09, 32:84-90.
-
6Garber A, Henry R, Rather R, et al. Liraglutide versusglimepiride monotherapy for type 2 diabetcs (LEAD-3 Mono) :a randomised, 52 week, phase Ⅲ, double-blind, paralMtreatment trial [J]. I.ancet, 2009, 373(9662):473- 481.
-
7Zinman B, Gerieh J, Buse JB, el al. Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog I.iraglutide in Combi nation With Metfomlin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met + TZD) [J]. Diabetes Care, 2009, 32:1224- 1230.
-
8Russel-Jones D, Vaag A, Schmitz O, et al. I.iraglutide vs in- sulin glargine and placebo in combination with metformin andsulfonylurea therapy in type 2 diabetes mellitus (LEAI)-5 met + SU) : a randomised controlled trial [J]. Diabetologia, 2009, 52(10) :2046- 2055.
-
9Buse J, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6) [J]. Lancet, 2009, 374(9683):39-47.
-
10Matthews DR, Marre M, Le Thi TD, etal. Liraglutide, a hu- man GLP-1 analogue, significantly improves beta cell function in subjects with type 2 diabetes [J]. Diabetologia, 2008, 51 (Suppl 1 ) : 892.
同被引文献57
-
1彭晶晶,王江,戴文豪,谢雄,柳红.先导化合物结构优化策略(七)——肽类分子结构修饰与改造[J].药学学报,2020,55(3):427-445. 被引量:7
-
2HUSSAIN A, CLAUSSEN B, RAMACHANDRAN A. et al. Prevention of type 2 diabetes : A review [ J ]. Diabetes Res Clin Prac,2007,76930 (3) :317-326.
-
3LINNEBJER G H, KOTHARE P A,PARK S, et al. Effect of renal impairment on the pharmacokinetics of exenatide [ J]. Br J Clin Pharmacol,2007,64(3) :317-327.
-
4ROUBICEK T, MRA Z M, BARTLOVA M, et al. The influ- ence of 6-months treatment with exenatide on type 2 diabetes mellitus compensation , anthropometric and biochemical parameters [ J]. Vnitr Lek, 2010,56 ( 1 ) : 15- 20.
-
5VILSBOLL T. Liraglutide:a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus [ J ]. Expert Opin Investig Drugs,2007,16 (2) :231-237.
-
6葛均波,徐永健.内科学[M].第8版.北京:人民卫生出版社,2013.259~265.
-
7中华医学会糖尿病学分会.中国2型糖尿病防治指南(2010版)[J].中国医学前沿杂志(电子版),2011,3(6):1-56.
-
8王秀琴,李晓辉,张海港,杨丹莉.G蛋白抑制性多肽-27药动学测定方法的建立[J].中国药学杂志,2008,43(9):692-695. 被引量:1
-
9吴璇,马卫东,刘洪臣.胰岛素的植入式给药[J].国际口腔医学杂志,2008,35(4):430-432. 被引量:1
-
10周远大,何海霞,王柯静,陈万一,李娟,汤成泳.口服还原型谷胱甘肽片在大鼠肝、脑、肾组织中的分布及其药动学[J].中国新药与临床杂志,2008,27(12):924-928. 被引量:3
引证文献4
-
1谢红艳,高泓,李天浩,富晓旭,王钧冬,李燕,谢春光.从气精固散理论探讨益气养阴通滞法恢复血糖动态平衡的作用[J].四川中医,2022,40(10):30-33.
-
2张婉珠,梁斌鑫,王维.降糖药的研究现状及新进展[J].医药导报,2013,32(11):1455-1458. 被引量:14
-
3张宇.利拉鲁肽联合二甲双胍治疗肥胖2型糖尿病17例临床疗效观察[J].淮海医药,2015,33(1):94-94. 被引量:2
-
4董萍萍,张加余,魏永利,兀琦,徐静,李华健,代龙,王少平.土鳖虫活性肽LL8在大鼠体内的药动学及药效学研究[J].中草药,2021,52(15):4607-4613. 被引量:11
二级引证文献27
-
1温丽敏,许燕玲,李振,郑媛嘉,郭文峰.黄芪六一汤对2型糖尿病大鼠降糖作用的机制研究[J].中药材,2018,41(3):699-702. 被引量:9
-
2梁业飞,周有望,陶文.消胆胺联合阿嗪米特对糖尿病小鼠胆汁酸代谢的影响[J].医药导报,2015,34(2):146-150.
-
3张振宇.论老年糖尿病患者血糖管理的优化策略[J].健康导报(医学版),2015,20(3):205-205.
-
4俞颖,张会杰.我院2012-2014年口服降糖药临床应用分析[J].湖北民族学院学报(医学版),2015,32(4):60-63. 被引量:3
-
5唐娇艳,孙慧玲.基础胰岛素临床规范化使用优化管理项目在初始胰岛素治疗患者随访中的应用[J].护理学杂志,2016,31(5):74-76. 被引量:6
-
6范世宏,毛玉山.利拉鲁肽联合二甲双胍治疗初诊肥胖2型糖尿病的临床效果分析[J].中国现代医生,2016,54(11):26-28. 被引量:33
-
7杜其勇.降糖药物对血糖波动影响的研究进展[J].继续医学教育,2016,30(7):154-156. 被引量:1
-
8孙敏洁,郑嫦云.门诊2型糖尿病患者口服降糖药应用分析[J].中国现代医生,2016,54(23):88-90. 被引量:11
-
9郭小春,孔祥桂,闫海燕,刘辉鹏.GLP-1类似物通过调节胰岛β细胞功能对2型糖尿病的临床疗效[J].中国临床研究,2017,30(4):518-520. 被引量:11
-
10高乐,李志霞,杨俊,武珊珊,王巍巍,杨智荣,詹思延,孙凤.胰高血糖素样肽1受体激动剂类降糖药致2型糖尿病患者头疼和眩晕的网状Meta分析[J].药物流行病学杂志,2018,27(1):3-9. 被引量:8
-
1张永强,汤风强,王慧琛.HPLC测定胰达康胶囊中金银花的含量[J].首都医药,2008,15(18):48-49. 被引量:2
-
2于艳,于世杰,修丽丽,孙科峰.HPLC法同时测定祛瘀清胰颗粒中虎杖苷和黄芩苷[J].中成药,2013,35(5):964-966. 被引量:3
-
3孙树森,李新辰,韩容,赵志刚.2014年美国FDA批准的新分子实体与评价:感染和传染病治疗用药[J].药品评价,2015,12(2):8-14. 被引量:6
-
4唐甜甜,郭立新.肠促胰素类药物的不良反应[J].药品评价,2013(11):24-28. 被引量:6
-
5王兰明.胰胆道解痉药夫洛丙酮[J].北京医药,1994(4):36-38.
-
6顾明君,张本立,叶朝阳,刘一民,杨秀疆.环孢素对大鼠葡萄糖代谢及β细胞功能的作用[J].第二军医大学学报,1991,12(4):317-319.
-
7姬萍.他汀类药物对中老年人均有益处[J].国外医学情报,2003,24(2):27-27.
-
8武晋晓,闫铮.二甲双胍与那格列奈的联合用药[J].实用糖尿病杂志,2006,2(3):53-54. 被引量:5
-
9相洪琴.阿司匹林的心脏益处具有性别差异[J].国外医学情报,2006,27(4):40-41.
-
10吴文迅.那格列奈对胰岛素抵抗的改善作用[J].医药论坛杂志,2006,27(9):70-71. 被引量:2